Table 2.

Treatment-emergent adverse events in a Phase 1 dose ascending study of VGT-309 in healthy volunteers.

					Treatment-Emergent Adverse Events
Subject ID	Dose (mg/kg)	Age	Sex	Weight	Adverse Event	Severity	VGT-309 Relatedness
1009	0.016	32	M	86.5
1011	0.016	18	M	90.2	Pain at IVC site	Mild	Unrelated
1017	0.016	21	M	82.3
1019	0.016	19	F	67.8	Headache	Mild	Unrelated
1020	0.016	22	M	65
1021	0.016	29	F	79.9
1006	0.05	25	M	69.7
1018	0.05	22	M	59.5	Nausea Lightheadedness	Mild Mild	Related Related
1031	0.05	26	M	92.4
1032	0.05	22	F	67.9	Menstrual cramps	Mild	Unrelated
1036	0.05	42	M	83.6
1040	0.05	19	F	58.7
1045	0.16	37	F	73.1
1049	0.16	33	M	80.6
1051	0.16	21	F	66.5
1056	0.16	27	M	79.3
1059	0.16	22	M	70.9
1063	0.32	25	M	61.3	Postural dizziness	Mild	Unrelated
1070	0.32	51	F	83.5	Nausea Headache	Mild Moderate	Unrelated Unrelated
1071	0.32	19	F	63.7	Nausea Lower back pain	Mild Mild	Unrelated Unrelated
1073	0.32	27	F	63.3
1079	0.32	18	M	72.5	Loose bowel movement Infusion related reaction Chest pain	Mild Moderate Mild	Related Related Unrelated
1084	0.32	23	F	69.9
1013	Placebo	31	F	51.4
1024	Placebo	26	F	53.2
1010	Placebo	22	M	79
1035	Placebo	29	F	53
1042	Placebo	26	M	84.4	Right IVC site bruise Left cubital fossa bruising	Mild Mild	Unrelated Unrelated
1060	Placebo	25	F	55
1072	Placebo	40	M	92.7